HealthDay News — Bronchial thermoplasty (BT), which uses 3 radio-frequency treatments to open the airways of adults with asthma, is beneficial up to 2 years for patients with inadequately controlled asthma, according to a study presented at the American Thoracic Society (ATS) 2017 International Conference, held May 19-24 in Washington, DC.1
Geoffrey Chupp, MD, from Yale University in New Haven, Connecticut, and colleagues reported baseline and follow-up results from the Post-Food and Drug Administration Approval Clinical Trial Evaluating BT in Severe Persistent Asthma. Two hundred eight-four subjects aged 18 to 65 years taking inhaled corticosteroids and long-acting beta-agonists were enrolled. Two hundred seventy-nine had 1 of 3 BT procedures and 271 had all 3 procedures.
The researchers found that 78% of subjects had at least 1 severe exacerbation in the 12 months prior to first BT procedure, while 16% and 29%, respectively, had hospitalizations and emergency department visits. Overall, 50.6% and 45.4% of subjects had severe exacerbations in the first and second year of follow-up, respectively, while 14.4% and 12.7% had hospitalizations and 18.3% and 13.5% had emergency department visits.
“BT offers an alternative approach for patients who are inadequately controlled with medications designed to improve the control of their asthma,” Dr Chupp in a press release.2
The study was funded by Boston Scientific.
- Chupp G, Kline J, Khatri SB, et al. Post-approval study for bronchial thermoplasty (BT): results to 2 years. Presented at: American Thoracic Society (ATS) 2017 International Conference; Washington, DC; May 19-24. Abstract 5767.
- Bronchial thermoplasty helps asthma patients reduce severe attacks, hospitalizations and ER visits. New York, NY: American Thoracic Society. http://www.thoracic.org/about/newsroom/press-releases/conference/2017/chupp-bronchial-thermoplasty.php. Published May 24, 2017. Accessed May 25, 2017.